Anthrax vaccine adsorbed (BioThrax) - Emergent BioSolutions

Drug Profile

Anthrax vaccine adsorbed (BioThrax) - Emergent BioSolutions

Alternative Names: Anthrax vaccine adsorbed (AVA) - Emergent BioSoutions; BioThrax

Latest Information Update: 17 Aug 2016

Price : $50

At a glance

  • Originator Emergent BioSolutions
  • Class Anthrax vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anthrax
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Anthrax

Most Recent Events

  • 15 Aug 2016 The US FDA approves sBLA for large scale manufacturing of BioThrax in Building 55
  • 21 Jun 2016 The US FDA completes Pre-Approval Inspection of Building 55, BioSolutions’ manufacturing facility for BioThraX®
  • 17 Jun 2016 The US FDA sets PDUFA date of August 15, 2016 for sBLA review for the manufacture of BioThrax® in Building 55
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top